Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.
Also called NCT04603508
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 240 participants
- Sponsor
- EMS
- Registry
-
NCT04603508
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT04603508. Randomized; double masking; primary purpose treatment. Start 2023-03 (anticipated); primary completion 2025-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Dyslipidemia
- Intervention (Drug)
- BERLIM 25/10 association
- Intervention (Drug)
- EMPAGLIFLOZIN
- Intervention (Drug)
- ROSUVASTATIN CALCIUM
- Intervention (Other)
- BERLIM 25/10 ASSOCIATION PLACEBO
- Intervention (Other)
- EMPAGLIFLOZIN PLACEBO
- Intervention (Other)
- ROSUVASTATIN CALCIUM PLACEBO
- Lead sponsor
- EMS
Record details
- Record id
cardio:ct-nct04603508- Content hash
8236cb1530655dfa1bb7cc4068a5f5a6a5282fc620b119f1315ea8b0c66ed681